Researchers at Tel Aviv’s Sourasky Medical Center have discovered why most patients with estrogen receptor–positive metastatic breast cancer, who initially respond to endocrine treatments like tamoxifen, will eventually develop resistance to them. The finding can help develop new treatments.
http://www.ascopost.com/ViewNews.aspx?nid=10729